- Home
- News
- canada nova scotia
- microbiome
Refine by
Microbiome Articles & Analysis
170 news found
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. With LAA, scientists can now explore intricate genomic landscapes, facilitating groundbreaking discoveries and advancements in various branches of genomics. Long ...
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. Based in Taiwan and founded by Prof. Ying-Chieh Tsai, PhD, ...
Sirenas, a chemical discovery company harnessing computational metabolomics for “Natural Product” drug discovery, and Hume Supernatural, Inc. (“Hume”), a leading personal care product company, announced today that the companies have entered into a collaboration to bring new natural ingredients from diverse marine and terrestrial sources into the personal care space. The ...
BySirenas
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...
ByArdigen
Synbiotic Health, a market leader in the discovery, development, and commercialization of probiotic ingredients, announced that the company has expanded its R&D and commercial capabilities with the acquisition of a 43,000 sf facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialization of advanced probiotic ingredients for improved health. The Madison ...
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
ByArdigen
Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...
ByArdigen
Strategic tech leadership appointment comes as industries race to innovate as part of the Bio Revolution - driving demand for advanced, AI-augmented knowledge discovery capabilities Tarun’s impressive career of >25 years includes tech leadership positions in the financial and security sectors Eagle Genomics, the platform business pioneering the application of network science to ...
Today, Eagle Genomics, the software platform business pioneering the application of network science to biology,?announced its attendance at international tradeshow ACHEMA 2022 in Frankfurt, Germany next week (22-26 August) as a Microsoft Showcase Partner. Eagle Genomics will be featured in Microsoft’s ‘Digital Hub’ Innovation space under the theme “Eagle Genomics and ...
Ariana Pharma, the leading eXplainable Artificial Intelligence (xAI) drug development company, announce the appointments of Dr. Marion Soto as Vice President, Business Development and Bertrand Lellouche as Chief Financial Officer. The financial and commercial experience of Marion and Bertrand will further drive Ariana’s accelerated growth. Marion and Bertrand will be bringing their ...
A surge in research projects on the human microbiome - the complex ecosystem of microorganisms in the human gastrointestinal tract - is bolstering scientific understanding of health, disease and environment. Much of the research has focused on gut bacteria and viruses, leaving a third factor - fungi - little studied. An international consortium of scientists has conducted the first large-scale ...
JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has concluded a facility use agreement with KINS Co., Ltd. (KINS), a company with a database of human microbiome, for the Collaborative Lab, a collaborative research facility for startups, which was established in a new research laboratory at the "JSR Bioscience ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced the presentation of preclinical data supporting further investigation of a rationally designed microbial consortium candidate (DE486) to prevent or treat gastrointestinal (GI) mucositis – a common and often painful complication of radiation and ...
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year’s Meeting in person or by proxy. Right to participate In order to participate in ...
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 4, 2022, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet; that no dividend is made; discharge from liability granted to Board members and the managing director, that the Board shall consist of ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...